Biomarker testing in cancer management- can one size fit all?

Lynette M. Sholl; Balazs Halmos

doi:10.1038/s41416-022-01967-4

Biomarker testing in cancer management- can one size fit all?

Lynette M. Sholl, Balazs Halmos

Medicine

Research output: Contribution to journal › Editorial › peer-review

Abstract

Biomarker-guided treatment selection has transformed cancer management. Pruis et al. provide a powerful example of the challenges and promises of whole genome sequencing to match patients with advanced cancer for precision oncology studies and targeted therapies. Expanding genomic testing platforms are reviewed with a view towards future applications to inform clinical cancer research and practice.

Original language	English (US)
Pages (from-to)	1177-1179
Number of pages	3
Journal	British Journal of Cancer
Volume	127
Issue number	7
DOIs	https://doi.org/10.1038/s41416-022-01967-4
State	Published - Oct 19 2022

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41416-022-01967-4

Cite this

@article{a33b3c1f0fe24a7a8a8a325752bb8c84,

title = "Biomarker testing in cancer management- can one size fit all?",

abstract = "Biomarker-guided treatment selection has transformed cancer management. Pruis et al. provide a powerful example of the challenges and promises of whole genome sequencing to match patients with advanced cancer for precision oncology studies and targeted therapies. Expanding genomic testing platforms are reviewed with a view towards future applications to inform clinical cancer research and practice.",

author = "Sholl, {Lynette M.} and Balazs Halmos",

note = "Funding Information: LMS and BH have disclosed no relevant conflicts of interest with the content of this editorial. LMS discloses research funding from Genentech, Bristol Myers Squibb (to institution), consulting fees from Genentech, Eli-Lilly (to institution) and consulting fees from AstraZeneca, GV20 Therapeutics (to LMS). BH discloses research funding from Boehringer-Ingelheim, Astra-Zeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene and Janssen (to institution) and consulting fees from Astra Zeneca, Boehringer-Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus and Veracyte (to BH). Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2022",

month = oct,

day = "19",

doi = "10.1038/s41416-022-01967-4",

language = "English (US)",

volume = "127",

pages = "1177--1179",

journal = "British Journal of Cancer",

issn = "0007-0920",